BACKGROUND: @entity3657 ( @entity3657 ) affects 4% to 12% of @entity1 aged 55 to 70 years and 20% of @entity1 over 70 years. The most common complaint is @entity613 ( @entity613 ) characterised by @entity158 in the legs or buttocks that occurs with exercise and which subsides with rest. Compared with age-matched controls, @entity1 with @entity613 have a three- to six-fold increase in cardiovascular mortality. Symptoms of @entity613 , walking distance, and quality of life can be improved by risk factor modification, smoking cessation, and a structured exercise program. Antiplatelet treatment is beneficial in @entity1 with @entity613 for the reduction of vascular events but has not been shown to influence claudication distance. OBJECTIVES: To determine the effect of @entity1924 on improving walking distance and in reducing vascular mortality and cardiovascular events in @entity1 with stable @entity613 . SEARCH STRATEGY: The Cochrane @entity1095 Group searched their specialised register (last searched August 2006) and the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 3, 2006). We searched MEDLINE (1966 to November 2005), EMBASE (1980 to November 2005), several more specialised databases, and reference lists of articles. SELECTION CRITERIA: Double-blind, randomised controlled trials of @entity1924 versus placebo, or versus other antiplatelet agents in @entity1 with stable @entity613 or @entity1 undergoing vascular surgical intervention for @entity3657 . DATA COLLECTION AND ANALYSIS: Two authors independently assessed trials for selection and all three authors independently extracted data. MAIN RESULTS: Eight randomised controlled trials comparing @entity1924 with placebo were included. The @entity353 ( @entity353 ) for the @entity613 ( @entity613 ) was improved following treatment with @entity1924 100 mg twice daily ( @entity353 31.1; 95% confidence interval (CI): 21.4 to 40.9) and 50 mg twice daily ( @entity353 41.3; 95% CI: -7.1 to 89.7) compared with placebo. @entity1 receiving @entity1924 150 mg twice daily had an increased @entity613 ( @entity353 15.7; 95% CI: -9.6 to 41.0) compared with those receiving placebo. One study also included a comparison with pentoxifylline. In this study, @entity1 receiving @entity1924 had significant improvement in @entity613 compared with placebo. There was no increase in major adverse events including cardiovascular events or mortality in @entity1 receiving @entity1924 compared with placebo. AUTHORS' CONCLUSIONS: @entity1 with @entity613 should receive secondary prevention for @entity65 . @entity1924 has been shown to be of benefit in improving walking distance in @entity1 with @entity613 . There are no data on whether it results in a reduction of adverse cardiovascular events.

XXXX for @entity3657 .

@entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients', 'Participants', 'people'] @entity1095 :: ('MESH:D016491', 'Disease') :: ['Peripheral Vascular Diseases'] @entity353 :: ('MESH:D015431', 'Disease') :: ['WMD', 'weighted mean difference'] @entity3657 :: ('MESH:D058729', 'Disease') :: ['Peripheral arterial disease', 'PAD'] @entity1924 :: ('MESH:C045645', 'Chemical') :: ['Cilostazol', 'cilostazol'] @entity613 :: ('MESH:D007383', 'Disease') :: ['intermittent claudication', 'ICD', 'initial claudication distance', 'IC'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']
@entity1924 :: (MESH:C045645,Chemical) :: ['Cilostazol']
